Netherlands-based single-molecule analysis technology developer Lumicks has closed a $93m series D round backed by internet and telecommunications group SoftBank’s Vision Fund 2.
The round was co-led by Farallon Capital Management and Lauxera Capital Partners and included funds and accounts advised by T Rowe Price, Parian Global Management, Pura Vida Investments, Irving Investors, existing backer Gilde Healthcare and unnamed members of Lumicks’ management team.
Lumicks is developing single-molecule analysis technology for molecular biology research and immunotherapy development. Its tools include a microscopy system for the imaging of single-molecule interactions and another device for cell avidity analysis, which measures the strength of the interactions between immune cells and cancer cells.
The company was founded in 2014 and its technology is based on research conducted by professors Gijs Wuite, Erwin Peterman, Iddo Heller at Vrije Universiteit Amsterdam.
The majority of the funding will be used to expand Lumicks’ research and development as well as commercialisation activities for its z-Movi Cell Avidity Analyzer product. It had raised an undisclosed amount of series A funding in 2017.